Loading...
XJPX
4539
Market cap35mUSD
Dec 05, Last price  
1,528.00JPY
1D
0.33%
1Q
-5.39%
Jan 2017
-71.96%
Name

Nippon Chemiphar Co Ltd

Chart & Performance

D1W1MN
XJPX:4539 chart
P/E
18.75
P/S
0.17
EPS
81.49
Div Yield, %
3.27%
Shrs. gr., 5y
0.07%
Rev. gr., 5y
0.51%
Revenues
32.57b
+5.93%
20,918,000,00022,307,000,00023,982,000,00027,361,000,00028,513,000,00031,944,000,00031,893,000,00035,118,000,00035,602,000,00035,688,000,00035,331,000,00034,182,000,00031,757,000,00031,541,000,00032,506,000,00031,559,000,00030,748,000,00032,570,000,000
Net income
294m
P
390,000,000168,000,000270,000,000573,000,0001,439,000,0002,125,000,0001,887,000,0001,899,000,0001,961,000,0002,054,000,0001,160,000,000881,000,000436,000,000495,000,000700,000,000339,000,000-180,000,000294,000,000
CFO
-265m
L
-82,000,000-3,261,000,0001,889,000,0002,748,000,0001,753,000,0001,912,000,0001,892,000,0002,438,000,0002,450,000,0002,737,000,0003,188,000,0002,196,000,0001,394,000,0001,503,000,0001,801,000,000-916,000,000296,000,000-265,000,000
Dividend
Mar 30, 202650 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Nippon Chemiphar Co., Ltd., together with its subsidiaries, manufactures, markets, imports, exports, and sells, ethical pharmaceuticals and diagnostic agents in Japan and internationally. It offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. The company also develops NC-2400, a PPAR-delta agonist; NC-2500, a novel advanced xanthine oxidoreductase inhibitor for the treatment of hyperuricemia/gout; and NC-2600, a P2X4 receptor antagonist for the treatment of neuropathic pain. In addition, it develops NC-2700, a novel urate transporter 1 inhibitor that enhance excretion urate to urine; NC-2800, a delta opioid receptor agonist for the treatment of depression/anxiety; Uralyt-U, an alkalization therapeutic drug; Soleton, an analgesic and anti-inflammatory drug; and Calvan, a hypertension therapeutic drug. Further, the company provides quasi-drugs, nutrients, health foods, cosmetics, and various type of creams. It distributes its generic pharmaceuticals through wholesalers to hospitals and pharmacies. The company was formerly known as Hitachi Chemical Co., Ltd. and changed its name to Nippon Chemiphar Co., Ltd. in 1970. Nippon Chemiphar Co., Ltd. was founded in 1950 and is headquartered in Tokyo, Japan.
IPO date
Oct 01, 1971
Employees
872
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT